Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

At a median follow-up of 44.8 months, breast cancer patients receiving palbociclib plus fulvestrant had a median overall survival of 34.9 months compared to 28 months in the placebo plus fulvestrant group; these results only show a positive trend, but are not statistically significant [ 354 ].

also in 11,005 other papers

In this context, highly significant was a recent meta-analysis that was carried out on the basis of the data of 10,319 patients that were derived from 19 studies [ 302 ].

also in 132,142 other papers

The subsequent analysis of the overall survival showed a trend to a slight, but not significant improvement, in the Buparlisib-treated group versus the placebo (33.2 versus 30.4 months) [ 309 ].

also in 53,322 other papers